Opendata, web and dolomites

DeMILI

NON INVASIVE DIAGNOSTIC TEST SERVICE FOR “NON ALCOHOLIC FATTY LIVER DISEASE” MANAGEMENT

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DeMILI" data sheet

The following table provides information about the project.

Coordinator
Talemnology S.L. 

Organization address
address: SANTANDER 10, 3A
city: SAN JUAN DE AZNALFARACHE
postcode: 41920
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.talemnology.com/en/demili-2/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Talemnology S.L. ES (SAN JUAN DE AZNALFARACHE) coordinator 50˙000.00

Map

 Project objective

The overall objective of the project as a whole is to provide to the global clinical community a non-invasive diagnostic tool for the management of the NAFLD (Non Alcoholic Fatty Liver Disease) through an ON-LINE SERVICE OF DIAGNOSTIC TEST as alternative to Liver Biopsy.

This project innovative approach is based on two verified proprietary imaging biomarkers linked to the evidence of NASH existence (Non Alcoholic Steatohepatitis) and fibrosis staging in patients with NAFLD, as well as a robust analytical method based on the optical analysis of a liver MRI (Magnetic Resonance Imaging) for the evaluation of these biomarkers.

Currently, no validated non-invasive tests are available to differentiate simple steatosis from NASH. Unmet need for NAFLD management is the development of non-invasive methods able to detect NASH and predict advanced fibrosis in a cost-effective, immediate, widely available, and accurate way.

This project faces a global unmet need and proposes a solution with ambitions of global scope based on a business and operational model that can afford this approach from an European perspective.

With this proposal, Radiologists, Gastroenterologists, Hepatic doctors as well as primary care Doctors, will have access to an early screening of patients with NASH and therefore to an early and cost-saver approach to its treatment strategy, through an accurate on-line service of diagnostic tests based on a business model that anticipate a higher cost-effectiveness ratio compare to liver biopsy.

Our feasibility assessment under Phase I work expect to validate that the business idea is achievable by the analysis of the technical and economic related aspects with the proposal and, at the same time, identifying those key issues to face in Phase II, jointly to the clinic validation and regulatory process necessary of being developed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DEMILI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DEMILI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More